

**Supplementary Table 3.** Medications in each group during follow-up

|                     | Total patients                |                           | <i>P</i> |
|---------------------|-------------------------------|---------------------------|----------|
|                     | Medication-only group (n=276) | PFO closure group (n=161) |          |
| <b>At 30 days</b>   |                               |                           |          |
| Antiplatelet alone  | 231/276 (83.7)                | 146/161 (90.7)            | 0.057    |
| Anticoagulant alone | 28/276 (10.1)                 | 10/161 (6.2)              | 0.218    |
| Both                | 11/276 (4.0)                  | 5/161 (3.1)               | 0.835    |
| None                | 6/276 (2.2)                   | 0                         | 0.145    |
| <b>At 6 months</b>  |                               |                           |          |
| Antiplatelet alone  | 217/260 (83.5)                | 142/156 (91.0)            | 0.043    |
| Anticoagulant alone | 24/260 (9.2)                  | 6/156 (3.8)               | 0.063    |
| Both                | 10/260 (3.8)                  | 6/156 (3.8)               | >0.999   |
| None                | 9/260 (3.5)                   | 2/156 (1.3)               | 0.305    |
| <b>At 12 months</b> |                               |                           |          |
| Antiplatelet alone  | 199/249 (79.9)                | 126/152 (82.9)            | 0.544    |
| Anticoagulant alone | 24/249 (9.6)                  | 6/152 (3.9)               | 0.057    |
| Both                | 13/249 (5.2)                  | 9/152 (5.9)               | 0.942    |
| None                | 13/249 (5.2)                  | 10/152 (6.6)              | 0.729    |
|                     | Matched cohort                |                           | <i>P</i> |
|                     | Medication-only group (n=130) | PFO closure group (n=130) |          |
| <b>At 30 days</b>   |                               |                           |          |
| Antiplatelet alone  | 107/130 (82.3)                | 117/130 (90.0)            | 0.106    |
| Anticoagulant alone | 15/130 (11.5)                 | 8/130 (6.2)               | 0.190    |
| Both                | 6/130 (4.6)                   | 5/130 (3.8)               | >0.999   |
| None                | 2/130 (1.5)                   | 0                         | 0.478    |
| <b>At 6 months</b>  |                               |                           |          |
| Antiplatelet alone  | 103/124 (83.1)                | 112/126 (88.9)            | 0.252    |
| Anticoagulant alone | 15/124 (12.1)                 | 5/126 (4.0)               | 0.033    |
| Both                | 4/124 (3.2)                   | 7/126 (5.6)               | 0.555    |
| None                | 2/124 (1.6)                   | 2/126 (1.6)               | >0.999   |
| <b>At 12 months</b> |                               |                           |          |
| Antiplatelet alone  | 93/117 (79.5)                 | 99/122 (81.1)             | 0.873    |
| Anticoagulant alone | 14/117 (12.0)                 | 4/122 (3.3)               | 0.022    |
| Both                | 6/117 (5.1)                   | 9/117 (7.4)               | 0.653    |
| None                | 4/117 (3.4)                   | 10/117 (8.2)              | 0.195    |

PFO, patent foramen ovale.